BTIG Research Issues Positive Forecast for Denali Therapeutics (NASDAQ:DNLI) Stock Price

Denali Therapeutics (NASDAQ:DNLI) had its price objective boosted by BTIG Research from $36.00 to $38.00 in a research note issued to investors on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

Other equities analysts have also recently issued reports about the stock. Robert W. Baird raised their target price on shares of Denali Therapeutics from $29.00 to $32.00 and gave the company an “outperform” rating in a research note on Thursday. Wedbush cut their price target on shares of Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Thursday, December 11th. Wolfe Research assumed coverage on shares of Denali Therapeutics in a research note on Monday, February 23rd. They set a “peer perform” rating on the stock. UBS Group started coverage on shares of Denali Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating for the company. Finally, Jefferies Financial Group reissued a “buy” rating and set a $40.00 price target on shares of Denali Therapeutics in a research report on Monday, March 2nd. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $33.70.

Denali Therapeutics Stock Performance

Shares of NASDAQ DNLI opened at $22.47 on Wednesday. The stock has a 50 day moving average price of $20.41 and a 200 day moving average price of $17.80. Denali Therapeutics has a 52 week low of $10.57 and a 52 week high of $23.77. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.16 and a current ratio of 9.16. The stock has a market capitalization of $3.56 billion, a PE ratio of -7.57 and a beta of 1.02.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.02. During the same period last year, the business posted ($0.67) EPS. Analysts predict that Denali Therapeutics will post -2.71 earnings per share for the current fiscal year.

Insider Activity at Denali Therapeutics

In related news, CEO Ryan J. Watts sold 35,198 shares of Denali Therapeutics stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total transaction of $580,767.00. Following the completion of the sale, the chief executive officer directly owned 296,833 shares of the company’s stock, valued at approximately $4,897,744.50. This trade represents a 10.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Alexander O. Schuth sold 17,218 shares of the business’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $284,097.00. Following the completion of the sale, the insider owned 282,828 shares of the company’s stock, valued at $4,666,662. This trade represents a 5.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 12.50% of the company’s stock.

Institutional Investors Weigh In On Denali Therapeutics

A number of institutional investors have recently modified their holdings of DNLI. Vanguard Group Inc. grew its stake in shares of Denali Therapeutics by 8.9% in the fourth quarter. Vanguard Group Inc. now owns 13,057,890 shares of the company’s stock valued at $215,586,000 after acquiring an additional 1,064,972 shares in the last quarter. Baillie Gifford & Co. boosted its holdings in Denali Therapeutics by 6.2% in the 4th quarter. Baillie Gifford & Co. now owns 12,310,889 shares of the company’s stock valued at $203,253,000 after purchasing an additional 719,304 shares during the period. T. Rowe Price Investment Management Inc. grew its position in shares of Denali Therapeutics by 28.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 7,254,132 shares of the company’s stock worth $119,766,000 after purchasing an additional 1,615,565 shares in the last quarter. Temasek Holdings Private Ltd increased its holdings in shares of Denali Therapeutics by 30.9% during the fourth quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company’s stock worth $115,784,000 after purchasing an additional 1,657,142 shares during the period. Finally, State Street Corp raised its position in shares of Denali Therapeutics by 14.6% in the fourth quarter. State Street Corp now owns 6,263,371 shares of the company’s stock valued at $103,408,000 after buying an additional 799,110 shares in the last quarter. Institutional investors own 92.92% of the company’s stock.

Trending Headlines about Denali Therapeutics

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: FDA granted accelerated approval for AVLAYAH, the first FDA‑approved brain‑penetrant enzyme replacement therapy for Hunter syndrome; Denali says the drug will be available in the U.S. shortly and will be supported by patient services — material commercialization catalyst and validation of Denali’s TransportVehicle platform. Read More.
• Positive Sentiment: The approval was supported by strong Phase 1/2 biomarker data (≈91% reduction in CSF heparan sulfate by week 24), and the FDA awarded a Rare Pediatric Disease Priority Review Voucher (PRV) — both boost near‑term commercial value and optionality for future programs. Read More.
• Neutral Sentiment: Management hosted/announced a conference call and webcast to discuss FDA approval and launch plans — useful for investors seeking detail on launch timing, pricing, and commercial preparedness. Read More.
• Negative Sentiment: Approval is accelerated and conditional: continued marketing authorization may depend on confirmatory Phase 2/3 COMPASS results (clinical benefit verification), creating execution risk and potential regulatory downside. Read More.
• Negative Sentiment: Safety and label limitations: infusion‑related reactions, anemia and rare kidney events are listed risks; AVLAYAH is not recommended with other ERTs — these factors could affect uptake, dosing logistics and payer/physician adoption. Read More.
• Negative Sentiment: Quiver/filings note recent insider sales and mixed institutional positioning updates — minor governance/ownership signal to monitor as launch execution unfolds. Read More.
• Neutral Sentiment: Several short‑interest notices in the feed are reporting zero shares (data appears noisy); no clear short squeeze signal from those entries. Read More.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.